The integration of information about effectiveness of other drugs as well as their target genes and the information about genes whose expression is affected during ZIKV infection indicated that Sorafenib likely acts via its target genes, FLT3 and/or BRAF, but not via its alternative target genes VEGFR or PDGFR. In addition, the number of drugs to be screened was reduced from 774 to 64 by filtering potential drug candidates based on their network distance to ZIKV infection associated genes and additional phenotype relevant additional knowledge, such as contained in the ‘FDA pregnancy’ label. This evidence concerns the gene BRAF and Zika virus infectious disease.